Bringing Concepts to Practice: The Rapidly Evolving Treatment Landscape for CLL, featuring Challenging Case Discussions

Program Description

Despite success with chemoimmunotherapy combination regimens for chronic lymphocytic leukemia (CLL), challenges remain, and the adverse effects associated with these regimens can increase treatment discontinuation. While treatments for CLL have improved over the last decade, research is ongoing into options that may expand combination approaches as well as finite treatment durations while offering fewer adverse effects along with improved adherence and access. Utilization of currently preferred regimens that include BTK and BCL-2 inhibitors require pharmacists to consider patient-specific factors influencing management. In this continuation of information from the AMCP Annual 2022 Meeting, expert panelists will lead a discussion centered on the challenges affecting both the healthcare system and patients with CLL, including adverse effects, expanding treatment options, combination of IV and oral regimens, and economic burden. Cases discussed amongst the faculty panel will include practical tips for the management of the growing armamentarium of regimens for patients with CLL, formulary management, and resource utilization tactics. 

Target audience: Oncology pharmacists and managed care pharmacists

Type of activity: Application
Release date: August 12, 2022
Expiration date: August 12, 2023

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Apply recent clinical data when assessing treatment plans for patients with chronic lymphocytic leukemia (CLL).
• Explore the managed care strategies in optimizing clinical outcomes in the treatment of CLL.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-22-386-H01-P. The activity is available for CE credit through August 12, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Anthony J. Perissinotti, PharmD, BCOP has the following relevant financial relationships with commercial interests to disclose:
Consultant: AbbVie, BeiGene, Janssen

Melody Chang, RPh, MBA, BCOP and, Bonnie A. Labdi, PharmD, BCOP have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms